Aspira Women's Health Files 8-K

Ticker: AWHL · Form: 8-K · Filed: 2024-09-13T00:00:00.000Z

Sentiment: neutral

Topics: financial-statements, exhibits, sec-filing

TL;DR

Aspira Women's Health filed an 8-K on 9/13 for a 9/9 event, mostly financial docs.

AI Summary

Aspira Women's Health Inc. filed an 8-K on September 13, 2024, reporting an event on September 9, 2024. The filing primarily concerns financial statements and exhibits, indicating potential updates or disclosures related to the company's financial status. No specific dollar amounts or new material events were detailed in the provided excerpt.

Why It Matters

This 8-K filing signals that Aspira Women's Health Inc. is providing updated financial information or exhibits to the SEC, which could be relevant for investors monitoring the company's financial health.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, not indicating any immediate material adverse events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Aspira Women's Health Inc.?

The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and to provide Financial Statements and Exhibits, with the earliest event reported on September 9, 2024.

When was this 8-K filed with the SEC?

This 8-K was filed as of date September 13, 2024.

What is Aspira Women's Health Inc.'s state of incorporation and IRS Employer Identification Number?

Aspira Women's Health Inc. is incorporated in Delaware and its IRS Employer Identification Number is 33-0595156.

Where is Aspira Women's Health Inc. located?

The company's business address is 12117 Bee Caves Road Building III Suite 100, Austin, Texas 78738.

Does this filing indicate any specific new business developments or financial results?

The provided excerpt of the 8-K filing indicates it is for 'Financial Statements and Exhibits' and Regulation FD Disclosure, but does not detail specific new business developments or financial results within this section.

From the Filing

0000950170-24-106448.txt : 20240913 0000950170-24-106448.hdr.sgml : 20240913 20240913170935 ACCESSION NUMBER: 0000950170-24-106448 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 42 CONFORMED PERIOD OF REPORT: 20240909 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240913 DATE AS OF CHANGE: 20240913 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aspira Women's Health Inc. CENTRAL INDEX KEY: 0000926617 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330595156 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34810 FILM NUMBER: 241298546 BUSINESS ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-519-0400 MAIL ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: VERMILLION, INC. DATE OF NAME CHANGE: 20070824 FORMER COMPANY: FORMER CONFORMED NAME: CIPHERGEN BIOSYSTEMS INC DATE OF NAME CHANGE: 20000316 FORMER COMPANY: FORMER CONFORMED NAME: ABIOTIC SYSTEMS DATE OF NAME CHANGE: 19950407 8-K 1 awh-20240909.htm 8-K 8-K false 0000926617 0000926617 2024-09-09 2024-09-09   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 09, 2024     Aspira Women's Health Inc. (Exact name of Registrant as Specified in Its Charter)     Delaware 001-34810 33-0595156 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)           12117 Bee Caves Road Building III Suite 100   Austin , Texas   78738 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: 512 519-0400     (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   AWH   The Nasdaq Stock Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Item 7.01 Regulation FD Disclosure. On September 9, 2024, Aspira Women's Health Inc. (the “Company”) made a presentation available to investors. A copy of the Slide Deck is furnished as Exhibit 99.1 to this Current Report on Form 8-K filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits     Exhibit No. Description   99.1 Slide Deck Presented by Aspira Women's Health I

View on Read The Filing